Medpace Holdings overview after recent share performance

Medpace Holdings (MEDP) has drawn fresh attention after a solid move in its share price over the past month, inviting investors to review how its current valuation lines up with recent fundamentals.

That recent 12.6% 1 month share price return stands out against a weaker year to date share price return, while a 1 year total shareholder return of 56.9% suggests longer term holders have still been rewarded.

If you are comparing Medpace with other opportunities in healthcare, this could be a good moment to scan a wider set of clinical research and biotech players through 39 healthcare AI stocks.

With Medpace trading around $467.50 and an intrinsic value estimate that sits lower, along with a mixed set of recent returns, investors may question whether the current price still leaves upside or if the market is already pricing in future growth.

Most Popular Narrative: 6.5% Undervalued

Against the last close of $467.50, the most followed narrative pegs Medpace's fair value near $500, suggesting the market price trails that estimate.

The rapid revenue acceleration in 2025 is heavily influenced by a therapeutic mix shift toward faster-burning studies (such as metabolic trials) with higher reimbursable costs, increasing "pass-through" revenue that is less margin-accretive, which could result in lower underlying revenue and EBITDA growth once this project mix normalizes.

Read the complete narrative. Read the complete narrative.

Want to understand why a business built on clinical research could support a higher valuation? The narrative leans on steady earnings expansion, firm margins, and a future profit multiple that still sits below a key industry benchmark. Curious which specific growth and profitability assumptions have to hold for that fair value to stack up?

Result: Fair Value of $500.08 (UNDERVALUED)

However, it is worth considering that a declining backlog, along with higher staffing and trial costs, could pressure margins and limit how far this valuation narrative can extend.

Next Steps

If this mix of cautious and optimistic signals leaves you undecided, it is worth reviewing the underlying data, forward assumptions, and key rewards yourself. To see what has investors optimistic about Medpace, start with the 3 key rewards.

Looking for more investment ideas?

If Medpace has sharpened your focus, do not stop here. You can quickly widen your watchlist with other stocks that match different goals and risk levels.

• Target fresh opportunities that the market may be overlooking by scanning a screener containing 20 high quality undiscovered gems tailored to strong fundamentals and quality financial profiles.
• Prioritize resilience by checking out 68 resilient stocks with low risk scores that pair lower risk scores with business models built for steadier performance.
• Strengthen your portfolio’s foundation by reviewing companies in the solid balance sheet and fundamentals stocks screener (48 results) and focusing on robust finances before sentiment shifts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.